SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances raised full-year revenue outlook, attributed to stronger demand for Amtagvi and Proleukin, is driving the discussion, with traders viewing it as evidence of improving commercial momentum. The reaction is broadly bullish, while short-squeeze and takeover talk remains speculative and many are watching for upcoming lung-cancer data.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobiles change-of-control severance policy has fueled speculation about a potential buyout or strategic deal, though traders also emphasize that the policy is not evidence an acquisition is underway. The discussion is divided between buyout hopes and skepticism, with delayed updates on BlueBirds 1416 shipments and launches a recurring concern.

Carnival Corp. Ltd. engages in the operation of cruise ships. It operates through the following business segments: North America Cruise Operations, Europe Cruise Operations, Cruise Support, and Tour and Others. The North America Cruise Operations segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corporation Ltd.

Carnival Corp

Carnivals quarterly results are drawing attention after a reported earnings and revenue beat, while its forward outlook is prompting debate. Bulls are celebrating the results and a possible short squeeze; skeptics point to softer near-term earnings guidance and elevated fuel costs.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

New four-year AMT-130 data for Huntingtons disease is driving attention: disease-progression slowing on the cUHDRS measure fell to 44% from 80% at three years and was no longer statistically significant, weighing on shares. Traders are divided, with skeptics questioning the treatments durability while bulls argue the FDA review is based on the previously submitted three-year data and cite patient dropouts in the external comparison group.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

The FHFAs move to let Fannie Mae and Freddie Mac use VantageScore alongside FICO in mortgage pricing has raised concerns that FICOs long-standing advantage in mortgage credit scoring could weaken, driving a sharp selloff. Traders disagree on the impact: bears see a threat to its pricing power and moat, while bulls argue the market is overreacting and FICO remains an entrenched business.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

AstraZenecas strategic investment in Summit and clinical collaboration around ivonescimab are driving attention, with traders welcoming the funding and big-pharma validation. The community is also emphasizing that the deal is not a buyout and does not settle the separate FDA approval question, while debating whether the share move will hold or fade.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas selection for the U.S. Armys ALATTIS program to develop next-generation 10 kV silicon-carbide technology is driving attention, with traders viewing it as validation of the companys technology. The reaction is divided: bulls see longer-term potential, while skeptics note it is a prototype award with no disclosed value and question its near-term revenue impact as the initial pop fades.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlists new ITC complaint alleges that Micron and downstream customers Nvidia, Broadcom, and Google infringe its HBM patents used in AI computing, and seeks import-exclusion and cease-and-desist orders. Traders largely view the filing as added leverage that could lead to licensing deals, while others caution that it may mean a prolonged legal fight; some also point to weak price action and short-selling pressure.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

ZBCNs sharp move is prompting breakout and momentum chatter, with traders also speculating about Robinhood-related links and a possible BlackRock connection; the broader BlackRock tie-up remains unconfirmed. Some holders point to Zebecs payroll and card integrations as longer-term support, while skeptics question whether adoption is translating into sustained token demand.

Uranium Energy Corp. engages in the provision of uranium and titanium mining and related activities, including exploration, pre-extraction, extraction, and processing of uranium concentrates, and titanium minerals. It operates through the following geographical segments: Wyoming, Texas, Saskatchewan, and Others. The company was founded by Alan P. Lindsay and Amir Adnani on May 16, 2003 and is headquartered in Corpus Christi, TX.

Uranium Energy Corp

UECs fiscal 2026 results and operating update are driving discussion, with traders highlighting higher production, Burke Hollows contribution, and a debt-free balance sheet with substantial liquidity. Reactions are broadly encouraged by the execution and domestic uranium-growth story, though some remain cautious about ongoing losses and the stocks weak price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$BCRX 

Right now the company is basically:
1) Orladeyo = real revenue today  
2) Navenibart = next drug, but still ~2–3 YEARS away  

That gap matters.

Here’s the board:

If they get bought → $16–18+  
If they keep executing → $13–16 over time  
If competition hits → $7–9  
If pipeline disappoints → $5–7  

So at ~$10 you’re right in the middle.

That’s why a buyout makes sense — you’re getting paid NOW instead of waiting years and taking the risk something goes wrong.

Not complicated. Just risk vs reward.

Sell it.

Riley Alexander

ktrader1991

angeloc441

Bernard Lomax

Larry

Mikey

Darryl Mulder

justfkntrade

Mr. Phat

bryan

M. West Jr.

Garrett Lamb

Darian DelMastro

Sood

Mark

Jag Heer

no1patfan

patternshifter

Jeremy

Brendan Perry

John Hayes

Kris Mono

ron gee

zaltenbairt

StockTwits for iOS

Biocryst Pharmaceuticals Inc.

 

Right now the company is basically:
1) Orladeyo = real revenue today  
2) Navenibart = next drug, but still ~2–3 YEARS away  

That gap matters.

Here’s the board:

If they get bought → $16–18+  
If they keep executing → $13–16 over time  
If competition hits → $7–9  
If pipeline disappoints → $5–7  

So at ~$10 you’re right in the middle.

That’s why a buyout makes sense — you’re getting paid NOW instead of waiting years and taking the risk something goes wrong.

Not complicated. Just risk vs reward.

Sell it.

Money Mane

@Money_Mane in another 5 years this should be trading at least 25 on orladeyo alone if they’re hitting their 1b plus peak estimates

 in another 5 years this should be trading at least 25 on orladeyo alone if they’re hitting their 1b plus peak estimates

Blest

@Money_Mane   Sorry dude.  That was pure circular mush.  What point are you making and to who??  GL

   Sorry dude.  That was pure circular mush.  What point are you making and to who??  GL

Vander

@Vanderm98 It’s not “circular” — you just missed it.

At $10 you’re not early anymore.
You’re paying mid-range for:
• One asset carrying the story
• A 2–3 year gap to the next real driver

So upside = slower + conditional
Downside = immediate if anything cracks

That’s called balanced risk… not alpha.

 It’s not “circular” — you just missed it.

At $10 you’re not early anymore.
You’re paying mid-range for:
• One asset carrying the story
• A 2–3 year gap to the next real driver

So upside = slower + conditional
Downside = immediate if anything cracks

That’s called balanced risk… not alpha.

@Money_Mane   Ok, but I paid 7 and you went full circular.  Talked me in and out of it.  It’s all good.  I wasn’t listening anyway 😎.  I do like this bump. Makes me feel smart. 

GL.

   Ok, but I paid 7 and you went full circular.  Talked me in and out of it.  It’s all good.  I wasn’t listening anyway 😎.  I do like this bump. Makes me feel smart. 

GL.

StockTwits For Android 

derp derp

@Money_Mane @clownmarket couldn’t agree more. Perfect time to sell.

 couldn’t agree more. Perfect time to sell.

@Money_Mane There is no &quot;competition&quot; that is not already known about. Baseline is where we are now (maybe 7-8) with upside. Only setback would be Navenibart failure, but that is low chance IMO. 20+ if Navenibart data comes back good.

StockTwits Web

 There is no "competition" that is not already known about. Baseline is where we are now (maybe 7-8) with upside. Only setback would be Navenibart failure, but that is low chance IMO. 20+ if Navenibart data comes back good.